Concord Biotech jumped 2.97% to Rs 1,483 after the company received good manufacturing practices (GMP) certificate from Ministry of Health Pharmacy and Poisons Board (PPB), Republic of Kenya for its formulation facility located in Gujarat.
The Ministry of Health Pharmacy and Poisons Board, Republic of Kenya had conducted inspection of Unit II formulation facility located at Valthera-Dholka in Ahmedabad, Gujarat. The said inspection has been completed successfully, without any adverse remarks.Concord is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based active pharmaceutical ingredients (API) across immunosuppressants and oncology in terms of market share, based on volume in 2022.
The companys consolidated net profit rose marginally to Rs 77.57 crore in Q3 FY24 as compared with Rs 77.37 crore in Q3 FY23. Net sales stood at Rs 240.80 crore in Q3 FY24
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app